Presenters include Karen Gallant, Deputy Executive Director of CARB-X.

Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world.

With scientific promise comes interest from investors – a surge of biotech startups are utilizing CRISPR technology for many different applications such as at-home testing, in-clinic uses, and more. “This incredibly powerful repurposing of the bacterial immune system has created an outpouring of financial backing for small companies with revolutionary technological advancement in genome engineering-based ventures.”^[1]

On November 12th, we will explore this subject with presentations from experts in the field, startup companies innovating in this space, and investors looking to invest in these new applications.

To learn more, click here.